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THE EFFECTS OF COMORBIDITY, PRESCRIPTION DRUG USE,
AND MEDICAL UTILIZATION ON DULOXETINE INITIATION
IN PATIENTSWITH FIBROMYALGIA
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Mallett D2, Robinson RL3
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OBJECTIVE: Investigate factors predicting duloxetine initiation
among ﬁbromyalgia patients. METHODS: Using Cox propor-
tional hazards models, we investigated effects of baseline health
characteristics among ﬁbromyalgia patients on time to duloxet-
ine initiation from the later of index date (duloxetine market
entry (August 1, 2004)) or ﬁrst ﬁbromyalgia diagnosis. Charac-
teristics measured in the six-month pre-index period included
demographics, comorbidities, use of medications recommended
by American Pain Society (APS), specialty physician services, and
ﬁbromyalgia diagnosis stage (newly-diagnosed, established). It
included 7965 patients with 2+ ﬁbromyalgia claims (ICD-9
729.1) who were continuously eligible from February 1, 2004
through December 31, 2005. A total of 495 (6.2%) had a pre-
scription for duloxetine during the study period. Time to initia-
tion was measured from index date to the ﬁrst duloxetine
prescription. Observations were right-censored if they did not
initiate on duloxetine during the study period. As duloxetine
initiation was strongly associated with established diagnosis,
separate models were estimated for 5353 newly-diagnosed and
2612 established patients. RESULTS: Baseline medication use
served as the strongest predictor of duloxetine initiation. Use of
alpha-2-delta ligands, venlafaxine, SSRIs, TCAs, other antide-
pressants, opioid analgesics, and non-benzodiazepine sedatives
all were strong predictors of initiation (all p < 0.05). Dopamine
agonists and venlafaxine (hazard ratios: 2.913; 2.338) were the
strongest for newly-diagnosed, and alpha-2 delta ligands and
SSRIs (hazard ratios: 1.843; 1.819) for the established group.
Duloxetine initiation was associated with tramadol use, female
gender, later dates of diagnosis, chronic fatigue syndrome, and
use of non-MD mental health providers; patients seen by chiro-
practors were less likely to initiate duloxetine. In the established
group, those with mental health diagnoses and those visiting
rheumatologists were more likely to initiate duloxetine (hazard
ratios: 1.756, 1.476; both p < 0.01). CONCLUSION: Physician
type and prior use of APS-recommended drugs were important
predictors of duloxetine initiation. Variations in predictors exist
for newly-diagnosed and established ﬁbromyalgia patients.
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OBJECTIVE: To describe the use of gastroprotective (GP) strat-
egies among new chronic users of NSAIDs in The Netherlands by
GI Risk Factor (RF) score. METHODS: From the PHARMO
Record Linkage System, including among others linked drug-
dispensing and hospital records of approximately three million
individuals in The Netherlands, we selected new chronic users of
Coxibs or tNSAIDs between January 1, 2000 and December 31,
2004 in The Netherlands. Eligible patients had >=1 year history
before the 1st NSAID dispensing and >=1 year of follow-up
afterwards. Use of GP strategies was deﬁned as the use of PPI,
Coxib or both. Baseline GI RF score was based on: history of
GI drug use, high dose of NSAIDs, age >60 years, use of
corticosteroids/anticoagulants/SSRI, rheumatoid arthritis, heart
failure or diabetes with each condition accounting for one factor.
Chronic users were >60 days on therapy during the ﬁrst year of
follow-up. Switching was assessed among those with >=1 GI RF
during the 1st year of follow-up. RESULTS: Among 58,770 new
chronic NSAID users at baseline, 47,234 (80.4%) used tNSAID
alone, 7.9% used tNSAID +PPI, 10.2% used a Coxib alone and
1.6% used a Coxib +PPI. Mean (SD) number of GI RF among
these groups was 1.6 (2.1), 3.1 (1.3), 1.5 (1.5) and 2.8 (1.3),
respectively. Among 48,390 patients (82.3%) with GI RF score
of >=1, 20.9% used a GP strategy, but this increased with the
number of GI RF. Within the 1st year, 5.3% (n = 2067) and 4.8%
(n = 1843) of tNSAIDs users with >=1 GI RF switched to
tNSAIDs+PPI and Coxib alone respectively. CONCLUSION:
Gastroprotection in users of tNSAIDs was inadequate. Over
80% of tNSAIDs with >=1 GI RF did not receive any GPA and
<5% start one within a year. More research should show if GPA
was used for preventive reasons.
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OBJECTIVE: Despite accumulated evidence that obesity is sig-
niﬁcantly associated with elevated risk for many chronic condi-
tions; its prevalence has reached epidemic levels not only in the
general population but also among patients with established
heart disease. Rising obesity and its associated comorbidities will
increase signiﬁcant health and economic burdens. In-dept analy-
ses of obese patients admitted in Florida hospitals have not been
reported. The purposes of the study are: 1) to compare the
adjusted total hospital charges among patients who are normal
weight or non-obese, obese and morbidly obese, and 2) to
describe the frequencies of comorbidities between these groups.
METHODS: A retrospective analysis of 2005 data from the
Florida Agency for Health Care Administration (AHCA) was
utilized. From the de-identiﬁed hospital discharge ﬁle, records
with primary or secondary diagnosis of obese and morbidly
obese using the International Classiﬁcation of Diseases, Ninth
Edition (ICD 9) code were extracted. Chi-square statistics and
general linear models were used to compare differences between
three groups. RESULTS: Of all discharges in Florida
(N = 2,534,641) in 2005, 44,552 (1.8%), 83,718 (3.3%), and
2,406,371 (94.9%) records were morbidly obese, obese, and
non-obese, respectively. Age, gender, ethnicity, type of admis-
sion, discharge status, length of hospital stay, health insurance
status, and total hospital charges differed signiﬁcantly in three
groups. Additionally, age-, length of stay-, and health insurance-
adjusted total hospital charges (US$) were signiﬁcantly different
among non-obese (27,689), obese (30,676), and morbidly
obese (31,461) (p < 0.01). The most common comorbidity was
unspeciﬁed essential hypertension in all three groups. CONCLU-
SION: Because obesity is a major cause of human essential hyper-
tension, rising blood pressure and its associated comorbidities
will continue to impart their health and economic consequences
in Florida. Thus, consistent and timely medical care to evaluate
health risks among obese patients is imperative.
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